EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues

Ioannis A Voutsadakis, Antonia Digklia

Chinese Clinical Oncology · 2023

DOI: 10.21037/cco-22-108 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chinese Clinical Oncology, 2023. Verfasst von Ioannis A Voutsadakis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Sault Area Hospital, Sault Ste Marie, Ontario, Canada; Division of Clinical Sciences, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 11-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAdenocarcinomaCarcinoma, Pancreatic DuctalHumansProto-Oncogene Proteins p21(ras)DNA Copy Number VariationsBiomarkers, TumorMutationGenomicsTumor Suppressor Protein p53Smad4 ProteinCyclin-Dependent Kinase Inhibitor p16

Stichwörter der Autor:innen

Pancreatic adenocarcinomacopy number alterationsgenomicsmolecular pathologymutations

Substanzen

Proto-Oncogene Proteins p21(ras)Biomarkers, TumorTumor Suppressor Protein p53Smad4 ProteinTP53 protein, humanSMAD4 protein, humanKRAS protein, humanCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Sault Area Hospital, Sault Ste Marie, Ontario, Canada; Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
  • Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausannne, Switzerland.

Zitieren

APA

Voutsadakis, I. A., & Digklia, A. (2023). Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues. Chinese Clinical Oncology. https://doi.org/10.21037/cco-22-108

Vancouver

Voutsadakis IA, Digklia A. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues. Chinese Clinical Oncology. 2023. doi:10.21037/cco-22-108

BibTeX
@article{Voutsadakis2023,
  author = {Voutsadakis, Ioannis A and Digklia, Antonia},
  title = {Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues},
  journal = {Chinese Clinical Oncology},
  year = {2023},
  doi = {10.21037/cco-22-108}
}
Kostenlos starten →